Formula I Compounds Modulating Glutamate Transporters
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of compounds that effectively activate or upregulate glutamate transporters, such as EAAT2, to address abnormal reductions in glutamate transporter activity or excessive extracellular glutamate concentrations in the CNS, which are associated with various neurological disorders and injuries.
Innovation Solution
The development of specific compounds, including those of Formula I and II, or their enantiomers, diastereoisomers, tautomers, salts, or solvates, which are administered to enhance glutamate uptake and transporter activity, as demonstrated by their efficacy in mediating glutamate uptake and providing neuroprotective effects in neuronal cultures and animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If compounds are designed to activate glutamate transporters, then glutamate uptake is enhanced, but no rationally designed transporter activator has been identified so far
Solution Approach 1:
The patent applies parameter changes by modifying molecular structures (R1, R2, R3, Z, A1-A3 parameters in Formula I) to optimize glutamate transporter activation. The compounds systematically vary chemical parameters to achieve effective glutamate uptake enhancement while maintaining selectivity for EAAT2 transporters.
Solution Approach 2:
The patent uses compounds of Formula I as intermediary molecules that mediate between the available crystal structure data (from bacterial homologs and human EAAT1) and the desired functional outcome (glutamate transporter activation). These compounds serve as the missing link that translates structural knowledge into functional activators.
2Quantity of substance
If glutamate transporter activity is increased, then extracellular glutamate levels are reduced, but excessive extracellular glutamate leads to excitotoxicity and neuronal damage
Solution Approach 1:
The patent converts the harmful effect of excessive extracellular glutamate (excitotoxicity) into a beneficial therapeutic outcome by designing compounds that specifically activate glutamate transporters to enhance clearance. The harm of glutamate accumulation is transformed into a benefit through controlled activation of uptake mechanisms.
Solution Approach 2:
The patent applies preliminary anti-action by activating glutamate transporters before excitotoxic damage occurs. The compounds prevent the harmful cascade by proactively clearing extracellular glutamate, stopping the excitotoxicity pathway before it can cause neuronal damage.
3Productivity
If EAAT2 expression is upregulated, then glutamate clearance is improved, but current upregulators must be administered prophylactically and have low clinical relevance for acute conditions
Solution Approach 1:
The patent applies preliminary action by designing compounds that can be administered before acute events occur, preparing the system in advance. The compounds upregulate EAAT2 expression proactively, so when acute conditions arise, the enhanced transporter capacity is already in place to immediately clear glutamate and prevent excitotoxicity.
Solution Approach 2:
The patent introduces dynamics by creating a system where EAAT2 expression can be modulated in response to different conditions. The compounds enable the transporter system to adapt its capacity dynamically, providing both prophylactic protection and potential acute treatment capability depending on timing and dosage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively augment glutamate uptake, show neuroprotective properties, and reduce neuronal damage in models of ischemia, epilepsy, and neuropathic pain, indicating their potential in treating disorders related to abnormal glutamate regulation.
Implementation Method 1
Glutamate translocation is a multi-step process that uses energy derived from Na+ and K+ electrochemical gradients to move glutamate against its concentration gradient.
Data Source
AI summary
The present disclosure provides in one aspect compounds of Formula I. In certain embodiments, the compounds of the disclosure are useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compounds of the disclosure stimulate a glutamate transporter.